Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Leukemia

Drugs for Leukemia
Find financial assistance programs available for leukemia drugs. Read More ›

Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

Vidaza FDA Approved for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Tibsovo FDA Approved, with Azacitidine, for Newly Diagnosed Patients with Acute Myeloid Leukemia and IDH1 Mutation

Chronic Myeloid Leukemia Resource Navigator for Patients

Tecartus, a Gene Therapy, Now Approved for Patients with Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia
In October 2021, the FDA approved a second indication for Tecartus (brexucabtagene autoleucel), a novel, genetically modified CAR T-cell therapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More ›

Scemblix a New Oral Therapy Approved for Patients with Chronic Myeloid Leukemia
In October 2021, the FDA approved Scemblix (asciminib) for patients with chronic-phase Ph-positive chronic myeloid leukemia (CML) or CML associated with T315I mutation. Scemblix is a new type of drug that may improve outcomes over other therapies for some patients with CML. Read More ›

Fighting Is the Hard Part, but You Have to Try
At age 84, Inocencio Melendez-Schroder was diagnosed with stage IV leukemia and was told that chemotherapy and radiation would not be recommended. Soon after his death at home, his daughter, Barbara, was diagnosed with stage II leukemia and used her dad’s lessons to improve her prognosis. Read More ›

Combining Targeted Therapies in CLL
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL. Read More ›

A Comprehensive Analysis of COVID-19 in Patients with CLL
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL. Read More ›

Page 1 of 13